RxDoctor Payments Data

Jennifer Torres

Nurse Practitioner · Newark, NYNPI 1104308196

Payments from drug & device makers

$464in general payments, 2019–2025

Across 27 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$129
  • GSK$89
  • Boehringer Ingelheim$46
  • Sanofi$36
  • Caris MPI, Inc.$35
  • Grifols USA, LLC$32
  • plus $97 from 5 others

What the payments were for

  • Food & beverage$464100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$464 in reported general payments places this provider in the 80th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$17,129
Medicare patients
134
Services billed
208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate28$352,369
Trelegy ElliptaFluticasone/Umeclidin/Vilanter218$171,782
Breztri AerosphereBudesonide/Glycopyr/Formoterol193$125,672
Dupixent PenDupilumab25$94,990
Pirfenidone25$61,816
SymbicortBudesonide/Formoterol Fumarate117$29,366
Breo ElliptaFluticasone/Vilanterol52$26,844
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr40$26,360
Bevespi AerosphereGlycopyrrolate/Formoterol Fum44$19,054
Spiriva RespimatTiotropium Bromide35$18,805
Advair HfaFluticasone Propion/Salmeterol44$16,987
Combivent RespimatIpratropium/Albuterol Sulfate19$10,139
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$8,358
Fluticasone-SalmeterolFluticasone Propion/Salmeterol54$7,513
Albuterol Sulfate HfaAlbuterol Sulfate233$7,064

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat$46$389,67298 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$89$232,051330 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$129$174,091354 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Newark

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →